The long-term safety of fibrates is still a topic of ongoing research. While they are effective in managing dyslipidemia, the chronic use of fibrates requires careful consideration of the risk-benefit ratio. The potential for cumulative toxicity, particularly in vulnerable populations, underscores the importance of individualized treatment plans and ongoing surveillance.
